CHANDAN HEALTHCARE LIMITED

Reg Off. Add: Biotech Park, Sector- G, Jankipuram, Kursi Road, Lucknow-226021
CIN: L85110UP2003PLC193493
TEL NO.: - 8069366666 **Email:** secretarial@chandan.co.in
www.chandandiagnostic.com

Date: 07 September 2026

To,
The Manager – Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051

Scrip Symbol: CHANDAN | **ISIN:** INE0B2N01016

Sub: Outcome of the Board Meeting held on Monday, 07 September 2026 – Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III thereto and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

Dear Sir/Madam,

We wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. Monday, 07 September 2026, which commenced at 04:00 p.m. and concluded at 04:30 p.m., has inter alia transacted the following business:

1. Appointment of Independent Director – recommendation to Members

On the recommendation of the Nomination and Remuneration Committee, recommended to the Members the appointment of Mr. Sanjay Srivastava (DIN: 11927967) as an Independent Director of the Company, not liable to retire by rotation, for a term of five (5) consecutive years commencing from 30 September 2026 up to 29 September 2031, subject to the approval of the Members at the ensuing Annual General Meeting. Details as required under the SEBI Circular dated 13 July 2023 are enclosed as Annexure A.

2. Ratification of remuneration of Cost Auditor for FY 2026-27

On the recommendation of the Audit Committee, approved the remuneration of Rs. 1,25,000/- per annum plus applicable taxes and reimbursement of out-of-pocket expenses payable to M/s Rahul Jain & Associates, Cost Accountants, Ghaziabad (Firm Registration No. 101515), for the audit of the cost records of the Company for the financial year ending 31 March 2027, and recommended the same to the Members for ratification at the ensuing Annual General Meeting.

3. Variation in the objects and utilisation of the proceeds of the preferential issue of convertible warrants

Recommended to the Members, for approval by way of a Special Resolution, the variation in the objects and utilisation of the unutilised proceeds of the preferential issue of 44,50,000 convertible warrants approved by the Members on 06 November 2025, to the extent of Rs. 50,00,00,000, from acquisition of business units, existing diagnostic centres, equipment, laboratories and other related assets, to business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres. Details are enclosed as Annexure B.

The above information is also being hosted on the website of the Company at www.chandandiagnostic.com.

You are requested to take the above on record.

Thanking you,

Yours faithfully,
For Chandan Healthcare Limited

RAJEEV NAIN
Digitally signed by RAJEEV NAIN
Date: 2026.09.07 16:36:40 +05'30'

Rajeev Kumar Nain
Company Secretary & Compliance Officer
Membership No.: A35449

Encl: Annexures A and B

ANNEXURE A

Details of the appointment of Mr. Sanjay Srivastava as an Independent Director, pursuant to Regulation 30 of the SEBI Listing Regulations read with Para A of Part A of Schedule III and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023

Sr. No.	Particulars	Details
1	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment, recommended by the Board on the recommendation of the Nomination and Remuneration Committee, subject to the approval of the Members at the ensuing Annual General Meeting, to strengthen the Board with expertise in indirect taxation, GST and regulatory affairs.
2	Date of appointment and term of appointment	Proposed appointment as an Independent Director, not liable to retire by rotation, for a term of five (5) consecutive years from 30 September 2026 to 29 September 2031, with effect from the date of approval by the Members at the Annual General Meeting to be held on 30 September 2026.
3	Brief profile	Mr. Sanjay Srivastava, aged 62 years, is a retired Additional Commissioner, State Goods and Services Tax, Government of Uttar Pradesh. He has extensive experience in taxation, indirect taxes, GST administration, regulatory affairs and public administration. He does not hold directorship in any other company and does not hold any shares in the Company.
4	Disclosure of relationships between directors	Mr. Sanjay Srivastava is not related to any Director or Key Managerial Personnel of the Company.
5	Information as required pursuant to the NSE Circular dated 20 June 2018 (Ref. No. NSE/CML/2018/24)	The Company confirms that Mr. Sanjay Srivastava is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India or any other such authority.

ANNEXURE B

Details of the proposed variation in the objects and utilisation of the proceeds of the preferential issue of convertible warrants

Sr. No.	Particulars	Details
1	Nature of the proposal	Variation in the objects and utilisation of the proceeds of the preferential issue of 44,50,000 convertible warrants approved by the Members by a Special Resolution passed on 06 November 2025.
2	Amount involved	Rs. 50,00,00,000, being the proceeds remaining unutilised as on date.
3	Existing objects	Acquisition of business units, existing diagnostic centres, equipment, laboratories and other related assets.
4	Revised objects	Business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres, in the manner and within the timelines set out in the Explanatory Statement to Item No. 4 of the Notice of the 23rd Annual General Meeting.
5	Rationale for the variation	The proposed variation does not involve the introduction of a new object. It only involves the reallocation of a portion of the unutilised proceeds originally earmarked for the acquisition of business units, existing diagnostic centres, equipment, laboratories and other related assets towards business expansion by setting up new diagnostic laboratories and comprehensive diagnostic centres. The proposed reallocation is being made to align the utilisation of the funds with the Company's current implementation plans and business requirements. The Company considers that establishing new diagnostic laboratories and comprehensive diagnostic centres will enable it to expand its diagnostic network, increase its service capacity and geographical presence, and support its long-term growth objectives.
6	Approval required	Special Resolution of the Members at the Annual General Meeting to be held on 30 September 2026. All other terms of the preferential issue, including the issue price, entitlement of the warrant holders, conversion ratio and the period within which the warrants may be exercised, remain unchanged.